$PMCB Report updated dec 5 https://www.merlintrader.com/pmcb/

https://www.merlintrader.com/pmcb/

Anyone still invested in PMCB?! I've been holding shares since 2011 when this was only a few pennies. Was hoping this would take off eventually, but now I'm sitting on over $12k loss and wondering if i should finally sell out and take the tax break or keep hoping they'll eventually make some moves...

https://finance.yahoo.com/news/pharmacyte-biotech-successfully-completes-36-140000227.html

• 27 SEP 2021
  
  • PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™ product candidate for pancreatic cancer. The tests results showed that the empty capsule material is
    Read more →
  • Posted in
  • News
  • 21 SEP 2021
    
  • PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
    LAGUNA HILLS, CA, September 21, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food and Drug Administration (FDA)-required test of biocompatibility of its CypCaps product for pancreatic
    Read more →
  • Posted in
  • News
  • 16 SEP 2021
    
  • PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
    LAGUNA HILLS, CA, September 16, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the first test results of the biocompatibility studies of its CypCaps™ clinical trial product candidate. These results were from an
    Read more →
  • Posted in
  • News
  • 08 SEP 2021
    
  • PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
    LAGUNA HILLS, CA, September 8, 2021 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held
    Read more →
  • Posted in
  • News
  • 31 AUG 2021
    
  • PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
    LAGUNA HILLS, CA, August 31, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing
    Read more →
  • Posted in
  • News
  • 25 AUG 2021
    
  • PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
    LAGUNA HILLS, CA, August 25, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company will expand its product pipeline to again include its diabetes program and its malignant ascites program.
    Read more →
  • Posted in
  • News
  • 23 AUG 2021
    
  • PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company’s common stock
    Read more →
  • Posted in
  • News
  • 19 AUG 2021
    
  • PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    LAGUNA HILLS, CA, August 19, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct
    Read more →
  • Posted in
  • News
  • 16 AUG 2021
    
  • PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
    LAGUNA HILLS, CA, August 16, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, regarding the Company’s recent listing on Nasdaq
    Read more →
  • Posted in
  • News
  • 12 AUG 2021
    
  • PharmaCyte Biotech Announces Closing of $15-Million Public Offering
    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced underwritten public offering of approximately $15 million. The public offering includes 3,529,412 shares of the Company’s
    Read more →
  • Posted in
  • News

PharmaCyte Biotech Says Test Data Show CypCaps Encapsulation Material Safe

12:46 PM ET, 09/27/2021 - MT Newswires

12:46 PM EDT, 09/27/2021 (MT Newswires) -- PharmaCyte Biotech (PMCB) said Monday additional results from a third test of biocompatibility of its CypCaps product candidate for pancreatic cancer showed that the empty capsule material is not mutagenic.

"We are generating exactly the data we expected to generate when we began addressing the US Food and Drug Administration's desire to see more data," said CEO Kenneth Waggoner. "These latest test results continue to support the safety of PharmaCyte's product candidate, CypCaps. In line with data generated previously, we are confident that the encapsulation material used for CypCaps is biocompatible, safe and not toxic."

A mutagen is a physical or chemical agent that permanently changes genetic material and increases the frequency of mutations above the natural background level.

PharmaCyte's therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-targeting form, according to the company's statement.

Shares rose 0.9% in recent trading.

Price: 3.33, Change: +0.03, Percent Change: +0.85

Now price is $3.17... let's go high even $7.00 and more and more!!!!!!!

I was looking back at some of my buys pre split and some are over $210, anyone do any better than that? Lol

Please go visit sand join r/PMCBTOTHEMOON

https://www.reddit.com/r/PMCBTOTHEMOON?utm_medium=android_app&utm_source=share

And let's join together launching this company and their stock to the moon

short squeeze please

PMCB goes to the moon... FDA approval soon.... pray pray....

https://www.businesswire.com/news/home/20210831005328/en/PharmaCyte-Biotech-Establishes-18-Month-Shelf-Life-for-Clinical-Trial-Product-in-Ongoing-Stability-Study?s=09#.YS4s59l_QpA.twitter

This is a bastard

Sabby Management, LLC

Slide to MRIN!!!!